11:38 AM EST - Concordia International Corp. : Commented on the issuance by the U.K. Competition and Markets Authority (CMA) of a Statement of Objections to Actavis U.K. (formerly Auden Mckenzie) and Concordia's International segment in relation to the supply of 10mg hydrocortisone tablets in the United Kingdom between 2013 and 2016. A statement of objections (SO) is a formal statement by the CMA that it considers that a competition infringement may have occurred. The Company commented: "We believe that the conduct of Amdipharm was not in breach of competition law. We will review the CMA's provisional position as set out in its Statement of Objections and then intend to respond in detail to it. Concordia International Corp.
shares T.CXR are trading up $0.04 at $2.79.